ArticleBritish journal of cancer2011
Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients.
Article in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis.Cancer medicine · 2020Pooled it
- Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer.BMC cancer · 2015Pooled it
- Article
- Plasma Circulating mRNA Profile for the Non-Invasive Diagnosis of Colorectal Cancer Using NanoString Technologies.International journal of molecular sciences · 2024Article
- Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer.International journal of molecular sciences · 2023Review
- Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer.Oncotarget · 2019Article
- Appendiceal carcinoma associated with microsatellite instability.Molecular and clinical oncology · 2018Article
- Homeobox protein CDX2 as a prognostic biomarker in solid malignancies: a meta-analysis.Oncotarget · 2017Article
- Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- Jagged 2 silencing inhibits motility and invasiveness of colorectal cancer cell lines.Oncology letters · 2016Article
- Identifying cancer origin using circulating tumor cells.Cancer biology & therapy · 2016Article
- Biology and significance of circulating and disseminated tumour cells in colorectal cancer.Langenbeck's archives of surgery · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur recent work has shown the feasibility of using a refined immunomagnetic enrichment (IE) assay to detect cytokeratin 20-positive circulating tumour cells (CK20 pCTCs) in colorectal cancer (CRC) patients. We attempted to improve the sensitivity for CRC by detecting another intestinal-type differentiation marker, CDX2 pCTCs, using the same methodology.
methodsCDX2 pCTCs were detected in patients with CRC, colorectal adenoma (CAD), benign colorectal diseases (BCD), other common cancers (OCC) and normal subjects (NS). Statistical analysis was used to correlate CDX2 pCTCs to the clinicohistopathological factors, recurrence, metastasis and survival after follow-up for 42 months in CRC patients.
resultsCDX2 pCTCs were detected in 81% CRC patients (73 out of 90, median number=21.5 CTCs), 7.5% CAD patients (3 out of 40), 0% patients with BCD (0 out of 90), 2.5% patients with OCC (2 out of 80) and 0% NS (0 out of 40). Furthermore, statistical analysis showed that CDX2 pCTC numbers were associated with tumour- node-metastasis stage and lymph node status. Using the median CDX2 pCTC numbers as the cutoff points, stratified groups of CRC patients had significant differences in their recurrence and survival.
conclusionsThis study showed that the refined IE assay can detect CDX2 pCTCs with high sensitivity and that CDX2 pCTCs can generate clinically important information for CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.